About
Oral, small molecule dopamine D2/D3 receptor antagonist
Areas of Focus
Categories
Small Molecule PharmaceuticalMidwest
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
857
By Phase
PHASE2: 4
By Status
RECRUITING: 1ACTIVE_NOT_RECRUITING: 1TERMINATED: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06899217Lead Sponsor
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
PHASE2Recruiting
400 participants
Started: Jan 29, 2025 · Completed: Jun 23, 2026
NCT05832151Lead Sponsor
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
PHASE2Active, not recruiting
382 participants
Started: Mar 27, 2023 · Completed: Dec 12, 2025
NCT04208698Lead Sponsor
A Scintigraphy Study in Adults With Diabetic Gastroparesis
PHASE2Terminated
2 participants
Started: Feb 17, 2020 · Completed: Mar 31, 2020
NCT04026997Lead Sponsor
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
PHASE2Completed
73 participants
Started: Sep 11, 2019 · Completed: Dec 17, 2020
Locations (1)
Headquarters
Cincinnati, OH, United States
Map
Loading map...